Adocia Welcomes a New Chief Financial Officer
Adocia, a well-known clinical-stage biopharmaceutical company that focuses on innovative solutions for diabetes and obesity, has recently undergone a significant leadership change. The company has appointed Mathieu-William Gilbert as its new Chief Financial Officer, taking over from Valérie Danaguezian, who dedicated over 18 years to the role.
Meet Mathieu-William Gilbert
Mathieu-William Gilbert brings extensive experience to Adocia, having previously worked at Novo Nordisk in various leadership roles. He held positions such as Vice President and General Manager at different subsidiaries in North Africa and Latin America. Gilbert joined Adocia in May 2024 as Chief Operating Officer and has shown strong skills in both commercial operations and financial management during his tenure.
Role and Responsibilities of the New CFO
In his new role, Gilbert will manage several key areas, including administrative and financial operations, investor relations, legal affairs, and human resources. Additionally, he will be part of the Executive Committee and serve as Secretary General for the Board of Directors.
Appreciation and Acknowledgments
Upon his appointment, Gilbert expressed gratitude, stating, "I thank Olivier Soula for his trust in adding the role of Chief Financial Officer to my position as Chief Operating Officer. It is with great pride that I commit to working alongside such a talented team. These past months have truly reinforced my confidence in Adocia's potential, and I am eager to help propel our success forward.”
The outgoing CFO, Valérie Danaguezian, has been instrumental in Adocia’s journey from its inception, significantly contributing her expertise as the company transitioned into a publicly traded entity. She had previously held key positions at several respected pharmaceutical companies before joining Adocia.
Looking Back on Achievements and Transitioning Roles
Reflecting on her nearly two decades at the company, Danaguezian said, "It is with great emotion that I leave Adocia after nearly two decades. I am proud to have been part of a remarkable team that embodies innovation and adaptability." Her departure was marked by careful planning and collaboration with Gilbert, ensuring a smooth transition as he steps into his new responsibilities.
The co-founders of Adocia, Olivier and Gérard Soula, shared their thoughts on Danaguezian’s departure, recognizing her outstanding contributions. Olivier Soula expressed excitement about Gilbert’s appointment, highlighting the valuable experience he brings. "Mathieu joins the team at a crucial time, and we are excited to harness his expertise to achieve our ambitious goals,” Soula remarked.
About Adocia and Its Focus on Innovation
Adocia is committed to advancing biotechnology, particularly in developing transformative therapeutic options for metabolic diseases like diabetes and obesity. The company boasts a diverse portfolio of drug candidates emerging from four proprietary technology platforms: BioChaperone, AdOral, AdoShell, and AdoGel. This innovative approach has established Adocia as a key player in the biopharmaceutical industry, supported by a strong pipeline and an extensive patent portfolio.
Based in Lyon, Adocia operates with a dedicated team of around 80 professionals who are focused on achieving scientific breakthroughs that benefit patients around the world. Their strategic emphasis on research and development aligns with their long-term vision of enhancing healthcare through innovation and excellence.
Frequently Asked Questions
Who is the new Chief Financial Officer of Adocia?
The new Chief Financial Officer of Adocia is Mathieu-William Gilbert, who has extensive experience in the biopharmaceutical industry.
What role did Valérie Danaguezian hold?
Valérie Danaguezian served as the Chief Financial Officer of Adocia for more than 18 years before her transition.
What experience does Mathieu-William Gilbert bring?
Gilbert has over fifteen years of experience at Novo Nordisk, where he held senior management positions in various regions.
What are the primary focuses of Adocia?
Adocia specializes in developing therapeutic solutions for diabetes and obesity, utilizing innovative technology platforms.
Where is Adocia headquartered?
Adocia is headquartered in Lyon and employs around 80 professionals, emphasizing their commitment to innovation in healthcare.
